Clinical Trial

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

Study acronym: VIGILANT
Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Depemokimab is being developed as a treatment for individuals with moderate to severe Chronic Obstructive Pulmonary Disorder (COPD). The aim of this study is to assess the efficacy and safety of early initiation of depemokimab as an add-on medicine in participants with moderate to severe COPD with type 2 inflammation.
Protocol Amendment History 3 changes
notable Trial sites expanded: 6 -> 121 locations 2026-07-29
notable Primary completion moved earlier: 2029-11-02 -> 2029-04-30 2026-07-29
minor Completion moved earlier: 2029-12-14 -> 2029-06-08 2026-07-29
Trial Details
NCT Number NCT07177339
Lead Sponsor GlaxoSmithKline
Conditions Pulmonary Disease, Chronic Obstructive
Enrollment 1,196 participants
Start Date 2025-10-20
Primary Completion 2029-04-30 (estimated)
Study Completion 2029-06-08 (estimated)
Updated on ClinicalTrials.gov 2026-07-28